What are the common side effects of mitotane and how should they be managed?

Side Effects of Mitotane

Mitotane causes significant toxicity in virtually all patients, with high rates of gastrointestinal, neurological, and endocrine adverse effects that require proactive monitoring and management to prevent life-threatening complications, particularly adrenal insufficiency which occurs universally. 1

Primary Side Effects and Their Management

Adrenal Insufficiency (Universal - 100%)

• Occurs in all patients due to mitotane's adrenolytic activity 1, 2
• Requires immediate glucocorticoid replacement:
  • Start hydrocortisone 50 mg/day (divided as 20-20-10 mg)
  • May need to increase to 80-100 mg/day due to mitotane's enzymatic induction of glucocorticoid metabolism 1
  • Monitor clinically; do not rely solely on cortisol levels as mitotane increases cortisol-binding globulin 3
• Mineralocorticoid insufficiency develops in 32-37% of patients, typically occurring late in treatment 2, 4
  • Add fludrocortisone based on blood pressure, potassium levels, and plasma renin activity 5

Gastrointestinal Toxicity (Very Common)

• Nausea, vomiting, diarrhea, and loss of appetite are dose-limiting 5, 6
• Management algorithm based on severity:
  • Grade 3/4 GI toxicity: Stop mitotane until symptoms resolve to grade 0-1 5
  • Upon resolution: Reduce dose by 1.5 g if mitotane level 14-20 mg/L, or reduce to 50-75% of previous dose if level >20 mg/L 5

Neurological Toxicity (Common)

• Dizziness, fatigue, amnesia, and cognitive impairment 3, 6
• Risk increases significantly above 20 mg/L plasma concentration 5
• Management for Grade 2 CNS toxicity:
  • Reduce daily dose by 1 g if mitotane level <14 mg/L
  • Reduce by 1.5 g if level 14-20 mg/L
  • Stop mitotane if level >20 mg/L 5
• Requires neurological examination every 2-4 weeks, especially in first months 7

Thyroid Dysfunction (45% of patients)

• Central hypothyroidism develops within 3-6 months 2, 4
• Characterized by decreased FT4; TSH is not a reliable marker 2
• Monitor TSH, fT3, fT4 every 3-4 months 5
• Replace with levothyroxine when clinically symptomatic 5
• Occurred in 36% of patients in adjuvant setting 4

Dyslipidemia (54% of patients)

• Both LDL-cholesterol and HDL-cholesterol increase significantly 2
• Hypertriglyceridemia also occurs 2
• Develops early - median onset at 6 months 4
• Monitor cholesterol (HDL, LDL) and triglycerides every 3-4 months 5
• Treat with statins NOT metabolized by CYP3A4 (pravastatin or rosuvastatin) if LDL/HDL consistently elevated 5
• 50% of patients required statin therapy 4

Male Hypogonadism (35-38% of males)

• Gynecomastia and hypogonadism occur after 3-6 months of treatment 2
• Testosterone replacement typically needed after >2 years 4
• Monitor testosterone, free testosterone, and SHBG in symptomatic males 5
• 34% required testosterone replacement in adjuvant setting 4

Female Reproductive Effects

• Ovarian cysts develop in 65% of pre-menopausal women 4
• Menstrual disorders less frequent 2
• Hypogonadism uncommon in fertile women 4
• Mitotane is teratogenic - pregnancy must be avoided for years after discontinuation due to persistent plasma levels 3

Hepatotoxicity

• GGT invariably elevated without clinical consequences 5
• Critical warning: If GOT, GPT, or bilirubin rapidly increase >3-fold baseline, stop mitotane immediately due to risk of liver failure 5
• Monitor liver enzymes initially every 4 weeks, then every 8 weeks after 6 months 5

Critical Monitoring Algorithm

First 3 Months (High-Risk Period)

• Mitotane levels every 2-3 weeks until plateau reached 5
• Clinical and neurological examination every 2-4 weeks 7
• Liver enzymes every 4 weeks 5
• Many toxicities (29-50%) occur before reaching target mitotane concentrations 4

After 3 Months

• Mitotane levels every 6 weeks once stable 5
• Liver enzymes every 8 weeks 5
• Thyroid function every 3-4 months 5
• Lipid panel every 3-4 months 5
• Renin every 3 months 5
• Blood count every 3-4 months 5

Important Clinical Pitfalls

Poor tolerance is extremely common - the majority of patients find mitotane markedly impacts quality of life 5. In recent studies, 100% of patients experienced adverse events, with 92% having 4 or more concurrent toxicities 8. However, only 7-8% discontinue due to adverse effects when properly managed 8.

Most side effects are reversible after mitotane discontinuation 2, but the drug's very long half-life means effects persist for months after stopping 3.

The therapeutic window is extremely narrow (14-20 mg/L), with reduced efficacy below 14 mg/L and increased toxicity above 20 mg/L 1, 5. Dose adjustments must be guided by both plasma levels AND clinical toxicity, not levels alone 5.

Numerous drug interactions occur due to CYP3A4 induction 3. Avoid dexamethasone for glucocorticoid replacement as it is a strong CYP3A4 inducer 3.